Can You Get COVID-19 Again? Replay our May 22 HDLive!

Follow Our Live Coverage of COVID-19 Developments

Mosaic HIV-1 Vaccine Induces Responses in Humans, Monkeys

Mosaic adenovirus serotype 26-based vaccine induces immune responses in humans, rhesus monkeys

Please note: This article was published more than one year ago. The facts and conclusions presented may have since changed and may no longer be accurate. And "More information" links may no longer work. Questions about personal health should always be referred to a physician or other health care professional.

THURSDAY, July 12, 2018 (HealthDay News) -- A mosaic adenovirus serotype 26 (Ad26)-based HIV-1 vaccine induces immune responses in humans and rhesus monkeys, according to a study published online July 6 in The Lancet.

Dan H. Barouch, M.D., from Harvard Medical School in Boston, and colleagues conducted a multicenter, randomized, placebo-controlled, phase 1/2a trial involving 393 participants recruited from 12 clinics in east Africa, South Africa, Thailand, and the United States. Healthy HIV-1-uninfected participants who were considered at low risk for HIV-1 infection were randomized to one of seven vaccine combination groups or a placebo group. Four vaccinations were administered over a period of 48 weeks. A parallel study was performed to assess the immunogenicity and protective efficacy of the same Ad26-based mosaic vaccine regimens in rhesus monkeys.

The researchers found that all vaccine regimens demonstrated favorable safety and tolerability. Mild-to-moderate pain at the injection site was the most commonly reported solicited local adverse event. In humans, the mosaic Ad26/Ad26 plus high-dose gp140 boost vaccine was the most immunogenic and elicited Env-specific binding antibody responses, antibody-dependent cellular phagocytosis responses at week 52, and T-cell responses at week 50 (100, 80, and 83 percent, respectively). In rhesus monkeys, Ad26/Ad26 plus gp140 boost induced similar magnitude, durability, and phenotype of immune responses.

"The mosaic Ad26/Ad26 plus gp140 HIV-1 vaccine induced comparable and robust immune responses in humans and rhesus monkeys," the authors write.

Several authors disclosed financial ties to pharmaceutical companies, including Janssen Vaccines & Prevention, which funded the study.

Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Last Updated: